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Abstract
Background: Cisplatin is an important DNA-damaging anticancer drug that has been used to treat many cancer
types. However, the effectiveness of cisplatin treatment diminishes quickly as cancer cells develop resistance to the
drug, which eventually results in treatment failure. Caffeine is an ingredient contained in many food sources.
Caffeine can inhibit activities of both ATM and ATR, two important protein kinases involved in DNA damage-induced
cell cycle arrest and apoptosis. The effect of caffeine on cisplatin-based cancer treatment is not well known.
Methods: Caspase-3 activation and cell growth inhibition assays were used to determine the effect of caffeine on
cisplatin-induced apoptosis and cell growth in lung cancer cells. Real time PCR, immunoblotting, and flow cytometry
assays were used determine a mechanism through which the presence of caffeine increased cisplatin-induced
apoptosis of the lung cancer cells.
Results: Our caspase-3 activation studies demonstrated that the presence of caffeine increased the cisplatin-induced
apoptosis in both HTB182 and CRL5985 lung cancer cells. Our cell growth inhibition studies indicated that the presence
of caffeine caused a more increase for cisplatin-induced cell growth inhibition. The results obtained from our real time
PCR and western blot studies revealed that the presence of caffeine increased cisplatin-induced expression of the PUMA
pro-apoptotic protein in these lung cancer cells. The results of our protein phosphorylation studies indicated that the
presence of caffeine caused a decrease in CHK1 phosphorylation at Ser317/Ser345 but an increase in ATM phosphorylation
at Ser1981 in the lung cancer cells treated with cisplatin. In addition, our flow cytometry studies also revealed that the
presence of caffeine caused an increase in G1 cell population but a decrease for cisplatin-induced cell cycle arrests at
the S and the G2 checkpoints in HTB182 and CRL5985 cells respectively.
Conclusion: Our results suggest that the presence of caffeine increases the cisplatin-induced lung cancer cell killings
by inhibiting ATR but inducing ATM activation, resulting in an increase in expression of PUMA protein and an increase
in apoptosis.
Keywords: Cisplatin treatment, Caffeine, ATR inhibition, ATM activation, PUMA expression, Apoptosis, Lung cancer cells

Introduction
Cisplatin is an anticancer drug that has been used to
treat many cancer types [1]. However, the effectiveness
of this drug often diminishes quickly due to development of cancer cell resistance to this drug [2]. Therefore,
approaches that can reverse cancer cell resistance phenotype or potentiate cancer cells to cisplatin treatment need
to be explored.
The anticancer action of cisplatin results from its ability to generate DNA damage (e.g. intra- and inter-strand
* Correspondence: g.wang@wayne.edu
Institute of Environmental Health Sciences, Wayne State University, 259 Mack
Avenue, Detroit, MI 48201, USA

DNA crosslinks) and to promote DNA damage-induced
cell cycle arrest and apoptosis [2,3]. However, cancer
cells can minimize or overcome the cytotoxicity of cisplatin using several different cellular mechanisms [2].
Nucleotide excision repair (NER), the major DNA repair
pathway used to repair bulky DNA damage generated by
many environmental carcinogens and therapeutic drugs,
is one of the major mechanisms used to remove cisplatin
DNA damage in cancer cells [4,5]. In addition, cancer
cells can also minimize the cytotoxicity of cisplatin with
other cellular mechanisms, such as altering cell membrane permeability to reduce cellular uptake of cisplatin
[1,6]. If the signal of cisplatin-induced cell cycle arrest/
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apoptosis could be enhanced, the effectiveness of cisplatin in cancer treatment would be greatly improved.
Caffeine is an ingredient contained in many of our
dietary sources, especially in beverages such as coffee,
tea, and other soft drinks. Caffeine is a known central
nervous system stimulant that acts through adenosine
receptors and monoamine neurotransmitters [7]. Caffeine is also a protein kinase inhibitor that inhibits a variety of protein kinases [8], including ATM and ATR, two
important protein kinases involved in DNA damageinduced cell cycle arrest and the apoptosis signaling
process [5,9,10]. Caffeine consumption is known to lower
cancer risk for certain types of cancer [11]. In addition,
studies reveal that caffeine inhibits DNA repair [12,13].
However, the effect of caffeine consumption on cisplatinbased cancer treatment is unknown.
We have studied the effect of caffeine on cisplatininduced apoptosis of lung cancer cells. Using HTB182
lung squamous carcinoma cells and CRL5985 lung
adenocarcinoma cells, the results of our caspase-3 activation studies demonstrated that the presence of caffeine
significantly increased the cisplatin-induced caspase-3
activation in these lung cancer cells. The results of our
cell survival studies revealed that the presence of caffeine enhanced cisplatin-induced cell growth inhibition
and apoptosis in these lung cancer cells. The results of
our real time PCR and western blotting studies indicated
that the presence of caffeine increased cisplatin-induced
expression of the PUMA pro-apoptotic protein in these
lung cancer cells. The results of our protein phosphorylation studies further revealed that the presence of caffeine caused a decrease in CHK1 phosphorylation at
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Ser317/Ser345 but an increase in ATM phosphorylation at
Ser1981 in the cisplatin-treated HTB182 and CRL5985
lung cancer cells. In addition, the results of our flow
cytometry studies also demonstrated that the presence
of caffeine caused an increase in G1 but a decrease in
either S or G2 phase cell population for the cisplatintreated HTB182 and CRL5985 lung cancer cells. All of
these results suggest that the presence of caffeine increases
the cisplatin-induced cell killing in both CRL5985 and
HTB182 lung cancer cells by inhibiting ATR activity,
resulting in an increase in apoptosis.

Results
The presence of caffeine caused a greater increase of
cisplatin-induced caspase-3 activation in both HTB182
and CRL5985 lung cancer cells

To determine the effect of caffeine on cisplatin-based
cancer treatment, we first determined the effect of caffeine on cisplatin-induced caspase-3 activation in both
HTB182 and CRL5985 lung cancer cells. The HTB182
and CRL5985 lung cancer cells were treated either with
cisplatin (10 μM) alone or in combination with both
caffeine (2 mM) and cisplatin (10 μM) for 36 hours and
caspase-3 activity was determined (Figure 1). As controls, caspase-3 activity was also determined from both
untreated and caffeine-treated HTB182 and CRL5985
lung cancer cells (Figure 1). Very low caspase-3 activity
was detected in the untreated or caffeine-treated HTB182
and CRL5985 cells (Figure 1). When treated by cisplatin
alone, a small increase in caspase-3 activity was observed
in both HTB182 and CRL5985 lung cancer cells (Figure 1).
However, when treated with both caffeine and cisplatin, a

Figure 1 Cisplatin-induced caspase-3 activation in both HTB182 and CRL5985 lung cancer cells. The lung cancer cells were first treated
with caffeine (2 mM) for 24 hours and then with cisplatin (10 μM) for 36 hours before caspase-3 activity was measured. The caspase-3 activity was
determined using the Ac-DEVD-AMC as a substrate and measured as nmol AMC/min/mg protein. The p value <0.01 was considered statistically
significant in this study (*p value < 0.01; **p value < 0.001).
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significant increase in caspase-3 activity was observed in
both HTB182 and CRL5985 lung cancer cells (Figure 1).
These results suggest that the presence of caffeine increased the cisplatin-induced apoptosis in both HTB182
and CRL5985 lung cancer cells.
The presence of caffeine resulted in an increase for
cisplatin-mediated cell growth inhibition in both HTB182
and CRL5985 lung cancer cells

To further determine the role of caffeine in cisplatinbased cancer treatment, we studied the effect of caffeine
on cisplatin-mediated cell growth inhibition of HTB182
and CRL5985 lung cancer cells (Figure 2). When treated
with caffeine alone, moderate inhibition in cell growth
was observed in both HTB182 and CRL5985 lung cancer
cells (Figure 2). When treated with cisplatin alone, some
cell growth inhibition was observed in HTB182 cells but
little effect on cell growth was observed in CRL5985
cells (Figure 2). However, when treated with the combination of caffeine and cisplatin, a much more severe inhibition in cell growth was observed in both HTB182
and CRL5985 lung cancer cells. In fact, the number of
live cells was significantly more decreased for the cells
treated with both caffeine and cisplatin than the untreated cells or the cells treated with cisplatin alone at
three and four days for both HTB182 and CRL5985 cells
(Figure 2). These results suggest that the presence of caffeine not only enhances the cisplatin-induced cell growth
inhibition but also increases the cisplatin-induced apoptosis in both HTB182 and CRL5985 lung cancer cells.
The presence of caffeine led to a greater increase of
cisplatin-induced PUMA expression in both HTB182 and
CRL5985 lung cancer cells

To define a mechanism through which the presence of
caffeine caused an increase of cisplatin-induced apoptosis in both HTB182 and CRL5985 lung cancer cells,
we determined the expression levels of BAD, Bcl-XL, and

PUMA, three important proteins involved in the DNA
damage-induced apoptosis process [14], in both untreated
and cisplatin/caffeine-treated HTB182 and CRL5985 lung
cancer cells (Figure 3). We first determined the mRNA
levels of Bad, Bcl-XL, and Puma genes in both untreated
and cisplatin/caffeine-treated HTB182 and CRL5985 cells
using a reverse transcription-based mRNA quantitation
(real time PCR) assay (Figure 3A). When treated with caffeine, some increase in mRNA levels was observed for
both Bcl-XL and Puma genes in the CRL5985 but not in
the HTB182 lung cancer cells (Figure 3A). When treated
with cisplatin, no significant increase was observed in any
of the Bad, Bcl-XL, or Puma genes in either CRL5985 or
HTB182 lung cancer cells (Figure 3A). When treated with
both caffeine and cisplatin, however, a significantly greater
increase in Puma mRNA was observed in both HTB182
and CRL5985 lung cancer cells (Figure 3A). Some increase
in Bcl-XL mRNA was also observed in the CRL5985 cells
treated with both caffeine and cisplatin (Figure 3A). However, this increase was not statistically significant in comparison to the Bcl-XL mRNA level in CRL5985 cells treated
with caffeine alone (Figure 3A).
We further determined the protein levels of PUMA
and BAD proteins in both untreated and caffeine/cisplatin-treated HTB182 and CRL5985 lung cancer cells
(Figure 3B). The results of our immuno-blotting studies
revealed that the cells treated with both caffeine and cisplatin displayed higher levels of PUMA protein than the
cells treated by caffeine or cisplatin alone in both HTB182
and CRL5985 cells (Figure 3B). However, the protein level
of the BAD, another pro-apoptotic protein, remained
unchanged with or without the caffeine and/or cisplatin
treatment in both HTB182 and CRL5985 cells (Figure 3B).
Given the important role of PUMA protein in DNA
damage-induced apoptosis, these results suggest that
induced expression of PUMA protein plays an important
role in caffeine increasing cisplatin-induced apoptosis of
HTB182 and CRL5985 lung cancer cells.
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Figure 2 The effect of caffeine on cisplatin-mediated cell growth inhibition in both HTB182 and CRL5985 lung cancer cells. The cells
were treated with 2 mM caffeine, 10 μM cisplatin, or a combination of 2 mM caffeine and 10 μM cisplatin. The cell growth rate was determined
at 24, 48, 72, and 96 hours after the treatment.
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A

B

Figure 3 Detection of Bad, Bcl-XL, and Puma expressions in both untreated and caffeine/cisplatin-treated HTB182 and CRL5985 lung
cancer cells. (A) The levels of Bad, Bcl-XL, and Puma mRNAs in both untreated and caffeine/cisplatin-treated HTB182 and CRL5985 lung cancer
cells as determined by real time PCR assay. (B) The levels of PUMA and BAD protein in both untreated and caffeine/cisplatin-treated HTB182
and CRL5985 lung cancer cells as determined by western blot assay. The p value <0.01 was considered statistically significant in this study
(**p value < 0.001).
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The presence of caffeine caused a decrease of CHK1
phosphorylation at Ser317/Ser345 and an increase of ATM
phosphorylation at Ser1981 in the cisplatin-treated
HTB182 and CRL5985 lung cancer cells

To define a mechanism through which the presence of
caffeine caused an increase of cisplatin-induced apoptosis
in the lung cancer cells, we determined the phosphorylation levels of CHK1 (Ser317/Ser345), ATM (Ser1981), and
p53 (Ser15), three proteins involved in the DNA damageinduced signaling process (5,8), from both untreated and
caffeine/cisplatin-treated HTB182 and CRL5985 lung
cancer cells (Figure 4). The results of our western blotting
revealed that the presence of caffeine caused a decrease of
CHK1 phosphorylation at Ser317/Ser345 but an increase of
ATM phosphorylation at Ser1981 in the cisplatin-treated
HTB182 and CRL5985 lung cancer cells (Figure 4). Interestingly, the p53 phosphorylation at Ser15 was detected
only in the cisplatin-treated CRL5985 cells and the presence of caffeine increased this cisplatin-induced p53 phosphorylation in the CRL5985 cells (Figure 4). Since the
Ser317/Ser345 of CHK1 protein are phosphorylated primarily by ATR kinase [15,16], these results suggest that the
ATR activity was inhibited in these lung cancer cells.
The presence of caffeine altered cell cycle profile of the
cisplatin-treated HTB182 and CRL5895 lung cancer cells

To further determine the mechanism through which the
presence of caffeine caused an increase of cisplatininduced apoptosis in the lung cancer cells, we also performed a flow cytometry assay to determine the cell
cycle profiles of the HTB182 and CRL5985 lung cancer
cells treated with caffeine and/or cisplatin (Figure 5).
The presence of caffeine resulted in an accumulation of
G1 cell population in both HTB182 and CRL5985 lung
cancer cells (Figure 5B vs A and F vs E). The cisplatin

Figure 4 The effect of caffeine on cisplatin treatment-induced
ATM, CHK1, and p53 phosphorylation in both HTB182 and
CRL5985 lung cancer cells. The cells were treated with caffeine
(2 mM) for 24 hours before the cisplatin treatment (10 μM). The cells
were collected 20 hours after the cisplatin treatment and used for
western blotting.
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treatment caused a S-phase arrest in the HTB182 cells
(Figure 5C vs A) and a G2-phase arrest in the CRL5985
cells (Figure 5G vs E). When treated with both caffeine
and cisplatin, however, the cisplatin-caused S and G2
arrests in these cells were diminished; instead, an increased G1-phase cell population was observed in these
cells (Figure 5D vs 5C and 5H vs 5G). This result suggests that the presence of caffeine altered cells cycle profiles in the cisplatin-treated HTB182 and CRL5985 lung
cancer cells.

Discussion
In this study, we determined the effect of caffeine on
cisplatin-induced apoptosis in lung cancer cells. The results of our caspase-3 activation studies demonstrated
that the presence of caffeine caused a significant increase
of cisplatin-induced caspase-3 activation compared to
cells treated by cisplatin alone in both HTB182 and
CRL5985 lung cancer cells. The results of our cell survival studies revealed that the presence of caffeine increased the cisplatin-induced cell growth inhibition and
cell killing in these lung cancer cells. The results of our
real time PCR and western blotting studies revealed that
the presence of caffeine caused a significant increase of
cisplatin-induced expression of PUMA protein in both
HTB182 and CRL5985 lung cancer cells compared to
cells treated by cisplatin alone. The results of our protein phosphorylation studies further demonstrated that
the presence of caffeine caused a decrease in CHK1
phosphorylation at Ser317/Ser345 but an increase in ATM
phosphorylation at Ser1981 in the cisplatin-treated HTB182
and CRL5985 cells. In addition, the results of our flow
cytometry studies revealed that the presence of caffeine
caused a decrease of cisplatin-caused S- and G2-phase cell
cycle arrests but an increase in G1 cell population in the
HTB182 and CRL5985 cells respectively. All of these results suggest that the presence of caffeine potentiates both
HTB182 and CRL5985 lung cancer cells to cisplatin treatment by inhibiting ATR activity but inducing ATM activation, resulting in an increase in expression of the PUMA
protein and an increase in apoptosis. These results not
only determined the effect of caffeine on cisplatin-induced
apoptosis in cancer treatment but also defined the molecular mechanism through which the presence of caffeine
caused an increase of cisplatin-induced apoptosis in these
lung cancer cells. Therefore, this information would have
important implications in cancer treatment, especially in
platinum-based cancer treatment.
Caffeine is a well-known protein kinase inhibitor that
inhibits a variety of protein kinases, including ATM and
ATR, two important protein kinases involved in DNA
damage-induced cell cycle arrest and apoptosis [17]. Our
CHK1 phosphorylation studies revealed that the presence of caffeine caused a decrease of cisplatin-induced
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Figure 5 The cell cycle profiles of both untreated and caffeine/cisplatin-treated HTB182 and CRL5985 lung cancer cells. Cells were either
untreated or treated with caffeine (2 mM) and/or cisplatin (10 μM). The cells were collected 20 hours after the cisplatin treatment and used for
flow cytometry assay. A propidium iodide-based DNA staining was used in the flow cytometry assay to stain DNA content in the fixed cells. The
corresponding captions used in the panels: (A) untreated HTB182; (B) HTB182 treated with caffeine; (C) HTB182 treated with cisplatin; (D) HTB182
treated with both caffeine and cisplatin; (E) untreated CRL5985; (F) CRL5985 treated with caffeine; (G) CRL5985 treated with cisplatin; (H) CRL5985
treated with both caffeine and cisplatin.

CHK1 phosphorylation at Ser317/Ser345 in both HTB182
and CRL5985 lung cancer cells, suggesting an inhibited
ATR activity in these cells [17,18]. The mechanism
through which inhibiting the ATR activity causes an increase of cisplatin-induced apoptosis in these lung cancer cells is unknown. However, work of others has
demonstrate the essential role of ATR-CHK1 pathway in
cell survival [19]. The results of our ATM phosphorylation studies also revealed that the presence of caffeine
caused an increase of cisplatin-induced ATM phosphorylation at Ser1981 in these lung cancer cells. Given the
important role of ATM phosphorylation at Ser1981 in activating the ATM protein and subsequent the ATM
signaling pathway [5,20], it is possible that inhibiting the
ATR-CHK1 pathway with caffeine enhances the cisplatininduced activation of the ATM signal pathway, which
further induces expression of important pro-apoptotic
proteins, including PUMA, to result in an increase in
apoptosis of these lung cancer cells. Although caffeine inhibits both ATM and ATR kinases activities, some studies
suggest that this inhibition is more effective in vitro than
inside cells [21]. It is possible that the level of caffeine used
in our studies (2 mM) only effectively inhibits the ATR
and the ATM activity maintained in these cells. In

addition, it is also possible that inhibiting the ATR-CHK1
pathway with caffeine leads to activation of other kinases,
especially the DNA-dependent protein kinase (DNA-PK),
in the cisplatin-treated cells which then induces expression of the apoptotic proteins and leads to increased apoptosis. DNA-PK can phosphorylate the p53 protein at Ser15
[22,23] and DNA-PK can be activated by DNA strand
breaks and DNA fragments [24]. Therefore, it would be
important to further determine the role of the ATM and
DNA-PK kinases in how caffeine potentiates these lung
cancer cells to cisplatin treatment in future studies.
Both our real time PCR and western blot results demonstrated that the presence of caffeine caused an increase of cisplatin-induced expression of the PUMA
protein in both HTB182 and CRL5985 lung cancer cells.
Given the important role of PUMA in apoptosis [14], it
is likely that induced expression of the PUMA protein
plays a role in caffeine potentiating lung cancer cells to
cisplatin treatment. Works of others have demonstrated
that both p53 and NF-κB can induce expression of the
PUMA protein [25,26]. Our p53 phosphorylation studies
revealed an induced p53 phosphorylation at Ser15 in the
cisplatin-treated CRL5985, suggesting a role of p53 activation in the cisplatin-induced PUMA expression of
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CRL5985 lung cancer cells (Figure 4). However, the
increased PUMA expression in cisplatin-treated HTB182
cells likely resulted from other mechanisms, especially
through activation of the NF-κB protein. It is known
that the NF-κB protein is inhibited by an active ATR
protein [27]. It is possible that inhibiting the ATR activity with caffeine eliminates this inhibiting effect, which
results in activation of the NF-κB and leads to a NF-κB
dependent PUMA expression in the p53-deficient
HTB182 cells. This observation has some very important
clinical implications in cancer treatment since a majority
of cancer patients are known to carry mutated or impaired
p53 proteins [6] and react poorly to the platinum-based
anticancer treatment.
The mechanism through which the presence of caffeine causes a greater increase of ATM activation in the
cisplatin-treated HTB182 and CRL5985 lung cancer cells
is unknown. One possible mechanism is that inhibiting
ATR activity with caffeine may prevent the cisplatincaused cell cycle arrest [28,29] and continued cell cycle
progression in the presence of cisplatin DNA damage
leads to an increase in DNA strand breaks and causes
activation of the ATM protein. Our flow cytometry study
provides some evidence to support this explanation since
our results revealed that the presence of caffeine reduced
the cisplatin-induced S and G2 arrests in HTB182 and
CRL5985 lung cancer cells. It is possible that the inability to arrest cells at the S and G2 phases in the cisplatintreated cells causes a continued cell cycle progression,
which results in an increase in DNA strand breaks and
an increase in ATM activation.
The results of our flow cytometry studies revealed that
cisplatin treatment caused S and G2 cell cycle arrests in
HTB182 and CRL5985 lung cancer cells respectively
whereas the presence of caffeine abolished this cisplatincaused cell cycle arrest and resulted in an increase of the
G1 cell population in these cells. This result is in agreement with our CHK1 phosphorylation results which
demonstrate a decreased CHK1 phosphorylation at
Ser317/Ser345 in the cisplatin-treated HTB182 and CRL5985
lung cancer cells in the presence of caffeine. Given the essential role of CHK1 phosphorylation in leading to S and
G2 cell cycle arrests [30], it is likely that inhibiting the
CHK1 phosphorylation with caffeine would eliminate the
cisplatin-caused S and G2 arrests, leading to accumulation
of G1 cells. In addition, this result also provides some
important insight into the mechanism through which the
presence of caffeine potentiates these lung cancer cells to
cisplatin treatment. It is known that most tumor cells are
deficient in the G1 checkpoint and reliant on the S and
G2 checkpoints to arrest cell cycle for DNA repair and cell
survival [31-33]; inhibiting the S and G2 checkpoints,
therefore, would prevent this process and enhance the
cisplatin-induced apoptotic signaling process in these
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tumor cells. Furthermore, it is known that one or more of
cell cycle checkpoint response components may be mutated or impaired in cancer cells, inhibiting the remaining
checkpoints likely will have a greater deleterious effect on
cancer cells than on normal cells with regard to DNAdamaging anticancer drugs, resulting in increased efficiency and specificity of these drugs in cancer cell killing.
Caffeine is widely consumed through our food sources,
especially through beverages such as coffee, tea, and
other soft drinks. Although many studies have demonstrated the beneficial effect of caffeine consumption in
lowering cancer risk [11], the effect of caffeine in cancer
treatment, especially in platinum-based cancer treatment, is unknown. The results of our studies demonstrate that the presence of caffeine potentiates lung
cancer cells to cisplatin-induced apoptosis. In addition,
results obtained from our recent DNA methylation studies suggest that the presence of caffeine may prevent
cigarette smoke-induced DNA hypermethylation of important tumor suppressor genes [34]. Therefore, it is
possible that caffeine consumption provides many beneficial effects, including its effect on cancer prevention
and treatment.

Materials and methods
Cell lines and primers used in the studies

Both HTB182 and CRL5985 cells were purchased from
the American Type Culture Collection (ATCC) (Rockville,
MD). The HTB182 were lung squamous carcinoma
cells derived from a Stage-2 lung cancer patients. The
CRL5985 were lung adenocarcinoma cells derived from
a Stage-4 lung cancer patient. Both HTB182 and
CRL5985 cells were maintained in RPMI1640 medium
supplemented with 10% fetal bovine serum (FBS) and
cultured at 37°C with 5% CO2.
The primers used in this study were listed in the
Table 1 and were synthesized by the Midland Certified
Reagent Company (Midland, TX). The PUMA primers
Table 1 Primers used in the real time PCR studies
1. PUMA primers:
PUMA forward primer:

5′-CTCGCTCTCGCTGGCGGAGCAG-3′

PUMA reverse primer:

5′-CGCTGCTGCTCTTGTCTC-3′

2. BAD primers:
BAD forward primer:

5′-GACGCCAGTCACCAGCAGGAG-3′

BAD reverse primer:

5′-CGTCACTCATCCTCCGGAGCTC-3′

3. Bcl-XL primers:
Bcl-XL forward primer:

5′-GGTGAGTCGGATCGCAGCTTG-3′

Bcl-XL forward primer:

5′-CTCTCGGCTGCTGCATTGTTC-3′

3. β-Actin Primers:
β-Actin forward primer:

5′GTACGTTGCTATCCAGGCTGTG3′

β-Actin reverse primer:

5′CATGAGGTAGTCAGTCAGGTC-3′
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were designed to bind to the Puma gene coding sequence between exon 2 and 3 to amplify a 200 bp cDNA
fragment. The BAD primers were designed to bind to
the Bad gene between exon 2 and 3 to amplify an
180 bp cDNA fragment. The BCL-XL primers were designed to bind to the coding sequence of Bcl-XL gene to
amplify a 122 bp cDNA fragment. The β-Actin primers
were designed to bind to the coding sequence of β-actin
gene (within exon 4) to amplify a 175 bp cDNA fragment.

purchased from Santa Cruz Biotechnologies Inc. (Santa
Cruz, CA).

Caffeine and cisplatin treatment

Competing interests
The authors declare that they have no competing interests.

Both caffeine and cisplatin were purchased from SigmaAldrich Company (St. Louis, MO). Caffeine was prepared as 100 mM stock in distilled water, filtered
through a 0.2 μm filter, and stored at −80°C. Cisplatin
was freshly prepared as a 100 mM solution in DMSO
and used immediately for each experiment.
Cells were seeded onto 100 mm cell culture dishes
and cultured at 37°C overnight to reach approximately
30% confluence. Some dishes were treated with caffeine
(2 mM) for 24 hours. The freshly prepared cisplatin
solution (100 mM) was then added into the cell growth
medium to a final concentration of 10 μM. For both
caspase-3 activation and western blotting of PUMA and
Bcl-XL studies, cells were collected 36 hours after the
cisplatin treatment. For western blotting of CHK1,
ATM, and p53 phosphorylation studies, cells were collected 20 hours after the cisplatin treatment.
Cell survival assay

Cells were seeded at 100 mm dishes and incubated at
37°C overnight to reach a density of approximately 20%
confluence. Cells were counted from one dish in each
cell line and were used as starting cell number for the
study. The rest of the dishes were treated with caffeine
(2 mM), cisplatin (10 μM), or a combination of both caffeine (2 mM) and cisplatin (10 μM). Cells were counted
from one set of dishes each day for four days. Trypan
blue was used to distinguish between live and dead cells
and only live cells were counted for the study. The
experiments were repeated four times and the data was
used to establish the cell growth curve using a GraphPad
software.
Caspase-3 activation and western blot assay

The caspase-3 activation assay was done using a protocol described in our previous study [35]. The western
blot assay was done using a protocol described in our
previous studies with some modification [35]. Essentially,
20 μg of total protein from each cell lysate was used in
the western blots. The p-ATM (Ser1981), p-CHK1 (Ser317),
pCHK1 (Ser345), and p-p53 (Ser15) antibodies were purchased from Cell Signaling Inc. (Beverly, MA). The PUMA
(G-3), BCL-XL, β-actin, and Tubulin antibodies were

Statistical analysis

All data was expressed as Mean ± standard deviation (S.D.).
Statistically significant differences were determined using
a student t-test with 95% confidence interval (CI). The
data was obtained from at least three independent
experiments.
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